Lucentis eye injection is a treatment for macular degeneration
Wet macular degeneration is one of the most common causes of blindness, Lucentis eye injection is a treatment.
Lucentis eye injection is a modern treatment for wet AMD, which develops in about 1 in 10 cases of macular degeneration. Above is a video explaining how Lucentis eye injection is used to treat wet macular degeneration. There are two types of macular degeneration: dry and wet macular degeneration. In the wet form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred vision or distorted vision. Without treatment, vision loss may be quick and severe.
The patient should consult their retina specialist / ophthalmologist about signs and symptoms of Lucentis side effects. Lucentis is an eye injection drug given by an eye surgeon. It is better and more effective than traditional laser eye surgery because it does not leave scarring in the macular central portion of vision. Lucentis was developed by Genentech and it is widely used for wet macular degeneration.
Lucentis side effects
Lucentis eye injection for treatment of macular degeneration has very few and rare side effects. The possibility of infection is extremely important to understand and the patient should consult their retina specialist / ophthalmologist about signs and symptoms of Lucentis side effects.
Other uses for Lucentis eye injection
Recently, Lucentis was approved for retinal vein occlusion and diabetic macular edema. These are two eye conditions that can cause profound vision loss. Adding Lucentis eye injection to the vitreo-retina doctor’s arsenal is a big advancement in the retina eye care field.
Diabetic macular edema is one of the leading causes of vision loss in the world. It is caused by weakened and leaky capillaries in the retinal vascular system, due to diabetes.
Retinal vein occlusion can also cause macular edema. This condition, also known as cystoid macular edema, as responded well to Lucentis eye injection. Lucentis is now a mainstream treatment for these two eye conditions.